Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference - Company achieved significant progress for its clinical pipeline in 2022 - - Precigen to host R&D Day virtual event o

Precigen Provides Pipeline and Corporate Updates

at the 41st Annual J.P. Morgan Healthcare Conference

Company achieved significant progress for its clinical pipeline in 2022 -

Precigen to host R&D Day virtual event on January 24, 2023, at 4:30 PM ET to share safety and efficacy data from the Phase

1 dose escalation and expansion cohorts of PRGN-2012 AdenoVerse immunotherapy in recurrent respiratory papillomatosis (RRP) -

GERMANTOWN, MD, January 11, 2023 -

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of

innovative gene and cell therapies to improve the lives of patients, today presented pipeline and corporate updates at the 41st Annual J.P.

Morgan Healthcare Conference. Helen Sabzevari, PhD, President and CEO of Precigen, presented a summary of 2022 achievements

and set forth Precigen's goals for 2023.

"Precigen continued to make significant clinical

progress for our UltraCAR-T and AdenoVerse programs in 2022 and we were able to meet or exceed substantially all of the clinical goals

we outlined at the J.P. Morgan Healthcare Conference last year. For example, the PRGN-2012 study in RRP continues to accelerate at a rapid

pace and we look forward to hosting an R&D update call on January 24th to share safety and efficacy data from the Phase 1 dose escalation

and expansion cohorts," said Helen Sabzevari, PhD, President and CEO of Precigen. "In 2023, we will continue to advance our

clinical programs with a focus on a rapid path to licensure for programs addressing high unmet patient need."

PRGN-2012 AdenoVerse Immunotherapy in RRP

PRGN-2009 AdenoVerse Immunotherapy in HPV-associated

PRGN-3006 UltraCAR-T in Acute Myeloid Leukemia (AML)

PRGN-3005 UltraCAR-T in Ovarian Cancer

PRGN-3007 Next Generation UltraCAR-T with Intrinsic PD-1

Precigen's J.P. Morgan

presentation is available on the Company website in the Events & Presentations section.

Precigen: Advancing Medicine with Precision

Precigen (Nasdaq: PGEN) is a dedicated discovery

and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target

the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.

Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an

innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and

Twitter @Precigen, LinkedIn or YouTube.

UltraCAR-T is a multigenic autologous CAR-T platform

that utilizes Precigen's advanced non-viral Sleeping Beauty system to simultaneously express an antigen-specific CAR to specifically target

tumor cells, mbIL15 for enhanced in vivo expansion and persistence, and a kill switch to conditionally eliminate CAR-T cells for a potentially

improved safety profile. Precigen has advanced the UltraCAR-T platform to address the inhibitory tumor microenvironment by incorporating

a novel mechanism for intrinsic checkpoint blockade without the need for complex and expensive gene editing techniques. UltraCAR-T investigational

therapies are manufactured via Precigen's overnight manufacturing process using the proprietary UltraPorator electroporation system

at the medical center and administered to patients only one day following gene transfer. The overnight UltraCAR-T manufacturing process

does not use viral vectors and does not require ex vivo activation and expansion of T cells, potentially addressing major limitations

of current T cell therapies.

AdenoVerse Immunotherapy

Precigen's AdenoVerse immunotherapy platform utilizes

a library of proprietary adenovectors for the efficient gene delivery of therapeutic effectors, immunomodulators, and vaccine antigens

designed to modulate the immune system. Precigen's gorilla adenovectors, part of the AdenoVerse library, have potentially superior performance

characteristics as compared to current competition. AdenoVerse immunotherapies have been shown to generate high-level and durable antigen-specific

neutralizing antibodies and effector T cell immune responses as well as an ability to boost these antibody and T cell responses via repeat

administration. Superior performance characteristics and high yield manufacturing of AdenoVerse vectors combined with UltraVector

technology allows Precigen to engineer cutting-edge investigational gene therapies to treat complex diseases.

The UltraPorator system is an exclusive device

and proprietary software solution for the scale-up of rapid and cost-effective manufacturing of UltraCAR-T therapies and potentially represents

a major advancement over current electroporation devices by significantly reducing the processing time and contamination risk. The UltraPorator

device is a high-throughput, semi-closed electroporation system for modifying T cells using Precigen's proprietary non-viral gene transfer

technology. UltraPorator is being utilized for clinical manufacturing of Precigen's investigational UltraCAR-T therapies in compliance

with current good manufacturing practices.

Precigen, UltraCAR-T, UltraPorator, AdenoVerse

and Advancing Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names may be trademarks of their

Cautionary Statement Regarding Forward-Looking

Some of the statements made in this press release

are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about

future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the

timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio

of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected

in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, including

the possibility that the timeline for the Company's clinical trials might be impacted by the COVID-19 pandemic, and actual future results

may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation

to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly

qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important

factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the

section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with

the Securities and Exchange Commission.

Vice President, Investor Relations

Tel: +1 (301) 556-9850